NCT04600440 (COP20) is a NA clinical trial of Convalescent plasma in Covid-19, sponsored by Skane University Hospital.

Who is sponsoring NCT04600440?

NCT04600440 is sponsored by Skane University Hospital.

What drugs are being tested in NCT04600440?

Interventions in NCT04600440: Convalescent plasma.

What condition does NCT04600440 study?

NCT04600440 studies Covid-19, Respiratory Insufficiency.

Is NCT04600440 still recruiting?

NCT04600440 is currently status unknown. Last updated 23 October 2020.

Last reviewed 2020-10-23 · How we verify

NCT04600440: COP20

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Convalescent Plasma in the Treatment of Covid-19

Status unknown NA Last updated 23 October 2020

What this trial tests

NA trial testing Convalescent plasma in Covid-19 in 100 participants. Status unknown.

Timeline

25 April 2020

Primary endpoint
31 December 2021

28 February 2022

Quick facts

Lead sponsor	Skane University Hospital
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	25 April 2020
Primary completion	31 December 2021
Estimated completion	28 February 2022
Sites	1 location across Sweden

Drugs / interventions tested

Convalescent plasma — full drug profile →

Conditions studied

Covid-19 — all drugs for Covid-19 →
Respiratory Insufficiency — all drugs for Respiratory Insufficiency →

Sponsor

Skane University Hospital

Who can join

18 and older, any sex, with Covid-19 or Respiratory Insufficiency. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

One hundred patients hospitalized and in need of oxygen treatment due to Covid-19 should be randomized and 50% treated with 200 ml convalescent plasma x 3 and 50% given ordinary treatment. Primary outcome is number of days the patients need oxygen within 28 days from inclusion. Secondary outcome is number of days in hospital, number of days in respirator and mortality. Side effects of treatment is monitored.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review.
Piechotta V, Iannizzi C, Chai KL, Valk SJ, et al · · 2021 · cited 106× · PMID 34013969 · DOI 10.1002/14651858.cd013600.pub4
COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes.
Focosi D, Franchini M, Pirofski LA, Burnouf T, et al · · 2022 · cited 79× · PMID 35262370 · DOI 10.1128/cmr.00200-21
Association between convalescent plasma treatment and mortality in COVID-19: a collaborative systematic review and meta-analysis of randomized clinical trials.
Axfors C, Janiaud P, Schmitt AM, Van't Hooft J, et al · · 2021 · cited 52× · PMID 34800996 · DOI 10.1186/s12879-021-06829-7
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 24× · PMID 36734509 · DOI 10.1002/14651858.cd013600.pub5
Convalescent plasma for people with COVID-19: a living systematic review.
Iannizzi C, Chai KL, Piechotta V, Valk SJ, et al · · 2023 · cited 21× · PMID 37162745 · DOI 10.1002/14651858.cd013600.pub6
Convalescence plasma treatment of COVID-19: results from a prematurely terminated randomized controlled open-label study in Southern Sweden.
Holm K, Lundgren MN, Kjeldsen-Kragh J, Ljungquist O, et al · · 2021 · cited 21× · PMID 34863304 · DOI 10.1186/s13104-021-05847-7
Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update.
Chavda VP, Bezbaruah R, Dolia S, Shah N, et al · · 2023 · cited 10× · PMID 36741339 · DOI 10.1016/j.procbio.2023.01.018
COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacy
Focosi D, Franchini M, Pirofski L, Burnouf T, et al · · 2021 · cited 4× · DOI 10.1101/2021.09.07.21263194

Verify or expand the search:

Other trials of Convalescent plasma

Trials testing the same drug.

NCT05077930 — Convalescent Plasma Therapy for Hospitalized Patients With COVID-19 · Phase 2 · completed
NCT04681430 — Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk Individuals · Phase 2 · completed
NCT04528368 — Convalescent Plasma for Treating Patients With COVID-19 Pneumonia Without Indication of Ventilatory Support · Phase 2 · unknown
NCT04497324 — PERUCONPLASMA: Evaluating the Use of Convalescent Plasma as Management of COVID-19 · Phase 2 · completed
NCT04747158 — COVID-19 Convalescent Plasma Therapy · Phase 2, PHASE3 · completed

Other recruiting trials for Covid-19

Currently open trials in the same condition.

NCT05943743 — Hiccups and Obstacles Of E-Learning Among Medical Sudents · recruiting
NCT04466683 — Low-Dose Radiotherapy For Patients With SARS-COV-2 (COVID-19) Pneumonia · Phase 2 · active not recruiting
NCT04433364 — COPE - COVID-19 in Pregnancy and Early Childhood · active not recruiting
NCT04568148 — COVID-19 Biorepository · active not recruiting
NCT04360538 — Long Term Outcomes of Patients With COVID-19 · active not recruiting

Other Skane University Hospital trials

Trials by the same sponsor.

NCT07426367 — Internet-Delivered ACT Targeting Emotional Distress and Chronic Pain · NA · not yet recruiting
NCT06214988 — Selective Defunctioning Stoma in Low Anterior Resection for Rectal Cancer · NA · recruiting
NCT06414382 — PSODEEP2 Pilot Study on Koebner Induction in Psoriasis · NA · not yet recruiting
NCT06153303 — Internet-based ACT for Endometriosis and Chronic Pain · NA · recruiting
NCT06122415 — The Swedish BioFINDER - Memory Clinic Study · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04600440 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Skane University Hospital
Last refreshed: 23 October 2020

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04600440.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing